TerminatedNot Applicable

EAMA Sarcopenia in Acute Care Patients in 9+European Countries

Stopped: COVID-19 pandemic and lack of funding necessary for continuation

Spain366 participantsStarted 2019-03-06

Plain-language summary

This collaborative study in 9 geriatrics units across Europe aims to apply emerging research to clinical practice, following the "Action-Research Philosophy" (11). The overall goal is to improve care in patients with - and help prevent - sarcopenia. Understanding the frequency of and risk factors for developing sarcopenia in an acute hospital setting, may help shed light on potential interventions and thus inform the development of future therapeutic strategies. It involves crucial implications for research, clinical practice, and policy towards optimal aging.

Who can participate

Age range

70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged \>70 admitted to acute hospital medical units Exclusion Criteria: * Length of hospital stay anticipated to be \<24 hours * Hip/lower limb fractures * Major amputations of the lower leg * Terminally ill patients admitted for palliative care

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Prevalence of sarcopenia as defined by the European consensus on definition and diagnosis (EWGSOP2)

Timeframe: One year (March 2019-March 2020)

Incidence of sarcopenia as defined by the European consensus on definition and diagnosis (EWGSOP2)

Timeframe: One year (March 2019-March 2020)

Trial details

NCT IDNCT04039620

SponsorParc de Salut Mar

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-04-02

View on ClinicalTrials.gov More Sarcopenia trials